nach oben

07.05.2024 | Brief Report

Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling

verfasst von: Gopinath Nagaraj, Elangovan Vellaichamy

Erschienen in: Endocrine

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Natriuretic peptide receptor-A (NPR-A) signaling system is considered as an intrinsic productive mechanism of the heart that opposes abnormal cardiac remodeling and hypertrophic growth. NPR-A is coded by Npr1 gene, and its expression is downregulated in the hypertrophied heart.

Aim

We sought to examine the levels of Npr1 gene transcription in triiodo-L-thyronine (T3) treated hypertrophied cardiomyocyte (H9c2) cells, in vitro, and also the involvement of β-adrenergic receptor (β-AR) - Reactive oxygen species (ROS) signaling system in the down-regulation of Npr1 transcription also studied.

Main methods

Anti-hypertrophic Npr1 gene transcription was monitored in control and T3-treated (dose and time dependent) H9c2 cells, using a real time PCR method. Further, cell size, intracellular cGMP, ROS, hypertrophy markers (ANP, BNP, α-sk, α-MHC and β-MHC), β-AR, and protein kinase cGMP-dependent 1 (PKG-I) genes expression were also determined. The intracellular cGMP and ROS levels were determined by ELISA and DCF dye method, respectively. In addition, to neutralize T3 mediated ROS generation, H9c2 cells were treated with T3 in the presence and absence of antioxidants [curcumin (CU) or N-acetyl-L-cysteine (NAC)].

Results

A dose dependent (10 pM, 100 pM, 1 nM and 10 nM) and time dependent (12 h, 24 h and 48 h) down-regulation of Npr1 gene transcription (20, 39, 60, and 74% respectively; 18, 55, and 85%, respectively) were observed in T3-treated H9c2 cells as compared with control cells. Immunofluorescence analysis also revealed that a marked down regulation of NPR- A protein in T3-treated cells as compared with control cells. Further, a parallel downregulation of cGMP and PKG-I (2.4 fold) were noticed in the T3-treated cells. In contrast, a time dependent increased expression of β-AR (60, 72, and 80% respectively) and ROS (26, 48, and 74%, respectively) levels were noticed in T3-treated H9c2 cells as compared with control cells. Interestingly, antioxidants, CU or NAC co-treated T3 cells displayed a significant reduction in ROS (69 and 81%, respectively) generation and to increased Npr1 gene transcription (81 and 88%, respectively) as compared with T3 alone treated cells.

Conclusion

Our result suggest that down regulation of Npr1 gene transcription is critically involved in T3- induced hypertrophic growth in H9c2 cells, and identifies the cross-talk between T3-β-AR-ROS and NPR-A signaling.

Y. Takahashi, T. Nakayama, M. Soma, Y. Izumi, K. Kanmatsuse, Organization of the Human Natriuretic Peptide Receptor A Gene. Biochem. Biophys. Res. Commun. 246(3), 736–739 (1998). https://doi.org/10.1006/bbrc.1998.8693CrossRefPubMed

D.G. Lowe, M.S. Chang, R. Hellmiss, E. Chen, S. Singh, D.L. Garbers, D.V. Goeddel, Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J. 8(5), 1377–1384 (1989). https://doi.org/10.1002/j.1460-2075.1989.tb03518.xCrossRefPubMedPubMedCentral

D.L. Garbers, Guanylyl cyclase receptors and their endocrine, paracrine, and autocrine ligands. Cell 71(1), 1–4 (1992). https://doi.org/10.1016/0092-8674(92)90258-eCrossRefPubMed

K.N. Pandey, Biology of natriuretic peptides and their receptors. Peptides 26(6), 901–932 (2005). https://doi.org/10.1016/j.peptides.2004.09.024CrossRefPubMed

L.R. Potter, T. Hunter, Phosphorylation of the Kinase Homology Domain Is Essential for Activation of the A-Type Natriuretic Peptide Receptor. Mol. Cell. Biol. 18(4), 2164–2172 (1998). https://doi.org/10.1128/mcb.18.4.2164CrossRefPubMedPubMedCentral

I. Mani, K.N. Pandey, Emerging concepts of receptor endocytosis and concurrent intracellular signaling: Mechanisms of guanylyl cyclase/natriuretic peptide receptor-A activation and trafficking. Cell Signal 60, 17–30 (2019). https://doi.org/10.1016/j.cellsig.2019.03.022CrossRefPubMedPubMedCentral

V. Cannone, A. Cabassi, R. Volpi, J.C. Burnett, Atrial natriuretic peptide: a molecular target of novel therapeutic approaches to cardio-metabolic disease. Int. J. Mol. Sci. 20(13), 3265 (2019). https://doi.org/10.3390/ijms20133265CrossRefPubMedPubMedCentral

I. Kishimoto, T. Tokudome, K. Nakao, K. Kangawa, Natriuretic peptide system: an overview of studies using genetically engineered animal models. FEBS J. 278(11), 1830–1841 (2011). https://doi.org/10.1111/j.1742-4658.2011.08116.xCrossRefPubMed

E. Vellaichamy, M.L. Khurana, J. Fink, K.N. Pandey, Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A. J. Biol. Chem. 280(19), 19230–19242 (2005). https://doi.org/10.1074/jbc.m411373200CrossRefPubMed

10.

P.M. Oliver, J.E. Fox, R. Kim, H.A. Rockman, H.S. Kim, R.L. Reddick, K.N. Pandey, S.L. Milgram, O. Smithies, N. Maeda, Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc. Natl Acad. Sci. USA 94(26), 14730–5 (1997). https://doi.org/10.1073/pnas.94.26.14730CrossRefPubMedPubMedCentral

11.

L.J. Ellmers, J.W. Knowles, H.S. Kim, O. Smithies, N. Maeda, V.A. Cameron, Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am. J. Physiol. Heart Circ. Physiol. 283(2), H707–14 (2002). https://doi.org/10.1152/ajpheart.00677.2001CrossRefPubMed

12.

E. Vellaichamy, D. Zhao, N. Somanna, K.N. Pandey, Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A up-regulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy. Physiol. Genomics 31(12), 193–202 (2007). https://doi.org/10.1152/physiolgenomics.00079.2007CrossRefPubMed

13.

D. Zhao, E. Vellaichamy, N. Somanna, K.N. Pandey, Guanylyl cyclase/natriuretic peptide receptor-A gene disruption causes increased adrenal angiotensin II and aldosterone levels. Am. J. Physiol. Renal Physiol. 293(1), F121–F127 (2007). https://doi.org/10.1152/ajprenal.00478.2006CrossRefPubMed

14.

S. Rubattu, G. Bigatti, A. Evangelista, C. Lanzani, R. Stanzione, L. Zagato, P. Manunta, S. Marchitti, V. Venturelli, G. Bianchi, M. Volpe, P. Stella, Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J. Am. Coll. Cardiol. 48(3), 499–505 (2006). https://doi.org/10.1016/j.jacc.2005.12.081CrossRefPubMed

15.

J. Wang, Z. Wang, C. Yu, Association of Polymorphisms in the Atrial Natriuretic Factor Gene with the Risk of Essential Hypertension: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health. 13(5), 458 (2016). https://doi.org/10.3390/ijerph13050458CrossRefPubMedPubMedCentral

16.

V. Gopi, V. Subramanian, S. Manivasagam, E. Vellaichamy, Angiotensin II down- regulates natriuretic peptide receptor-A expression and guanylyl cyclase activity in H9c2 (2-1) cardiac myoblast cells: role of ROS and NF-kB. Mol. Cell Biochem. 409(1-2), 67–79 (2015). https://doi.org/10.1007/s11010-015-2513-0CrossRefPubMed

17.

W. Song, H. Wang, Q. Wu, Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene 569(1), 1–6 (2015). https://doi.org/10.1016/j.gene.2015.06.029CrossRefPubMedPubMedCentral

18.

S. Manivasagam, E. Vellaichamy, Suppression of Npr1, not Npr2 gene function induces hypertrophic growth in H9c2 cells in vitro. Biochem. Biophys. Res. Commun. 491(2), 250–256 (2017). https://doi.org/10.1016/j.bbrc.2017.07.123CrossRefPubMed

19.

S. Manivasagam, V. Subramanian, A. Tumala, E. Vellaichamy, Differential expression and regulation of anti-hypertrophic genes Npr1 and Npr2 during β-adrenergic receptor activation-induced hypertrophic growth in rats. Mol. Cell Endocrinol. 433, 117–29 (2016). https://doi.org/10.1016/j.mce.2016.06.010CrossRefPubMed

20.

P. Kumar, R. Garg, G. Bolden, K.N. Pandey, Interactive roles of Ets-1, Sp1, and acetylated histones in the retinoic acid-dependent activation of guanylyl cyclase/atrial natriuretic peptide receptor-A gene transcription. J. Biol. Chem. 285(48), 37521–30 (2010). https://doi.org/10.1074/jbc.M110.132795CrossRefPubMedPubMedCentral

21.

U. Subramanian, P. Kumar, I. Mani, D. Chen, I. Kessler, R. Periyasamy, G. Raghavaraju, K. Pandey, Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice. Physiol. Genomics 48(7), 477–490 (2016). https://doi.org/10.1152/physiolgenomics.00073.2015CrossRefPubMedPubMedCentral

22.

S. Manivasagam, T. Velusamy, B. Sowndharajan, N. Chandrasekar, S. Dhanusu, E. Vellaichamy, Valporic acid enhances the Atrial Natriuretic Peptide (ANP) mediated anti-hypertrophic activity by modulating the Npr1 gene transcription in H9c2 cells in vitro. Eur. J. Pharmacol. 813, 94–104 (2017). https://doi.org/10.1016/j.ejphar.2017.07.042CrossRefPubMed

23.

I. Klein, S. Danzi, Thyroid disease and the heart. Circulation 116(15), 1725–1735 (2007). https://doi.org/10.1161/CIRCULATIONAHA.106.678326CrossRefPubMed

24.

S. Danzi, I. Klein, Thyroid disease and the cardiovascular system. Endocrinol. Metab. Clin. N. Am. 43(2), 517–528 (2014). https://doi.org/10.1016/j.ecl.2014.02.005CrossRef

25.

A. Jabbar, A. Pingitore, S.H. Pearce, A. Zaman, G. Iervasi, S. Razvi, Thyroid hormones and cardiovascular disease. Nat. Rev. Cardiol. 14(1), 39–55 (2017). https://doi.org/10.1038/nrcardio.2016.174CrossRefPubMed

26.

C.W. Siu, C.Y. Yeung, C.P. Lau, A.W.C. Kung, H.F. Tse, Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 93(4), 483–487 (2010). https://doi.org/10.1136/hrt.2006.100628CrossRef

27.

B. Biondi, Mechanisms in endocrinology. Heart failure and thyroid dysfunction. Eur. J. Endocrinol. 167(5), 609–18 (2012). https://doi.org/10.1530/EJE-12-0627CrossRefPubMed

28.

J.E. Mitchell, A.S. Hellkamp, D.B. Mark, J. Anderson, G.W. Johnson, J.E. Poole, K.L. Lee, G.H. Bardy, Thyroid function in heart failure and impact on mortality. JACC Heart Fail 1(1), 48–55 (2013). https://doi.org/10.1016/j.jchf.2012.10.004CrossRefPubMedPubMedCentral

29.

J.P. Bilezikian, J.N. Loeb, The influence of hyperthyroidism and hypothyroidism on α- and β-adrenergic receptor systems and adrenergic responsiveness. Endocr. Rev. 41(4), 378–387 (1983). https://doi.org/10.1210/edrv-4-4-378CrossRef

30.

L.W. Hu, L.A. Benvenuti, E.A. Liberti, M.S. Carneiro‐Ramos, M.L.M. Barreto‐Chaves, Thyroxine‐induced cardiac hypertrophy:Influence of adrenergic nervous system versus renin‐angiotensin system on myocyte remodeling. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285(6), 1473–1480 (2003). https://doi.org/10.1152/ajpregu.00269.2003CrossRef

31.

W. Dillmann, Cardiac hypertrophy and thyroid hormone signaling. Heart Fail. Rev. 15(2), 125–132 (2010). https://doi.org/10.1007/s10741-008-9125-7CrossRefPubMed

32.

A.P.C. Takano, N. Senger, C.D. Munhoz, M.L.M. Barreto‐Chaves, AT1 blockage impairs NF‐kB activation mediated by thyroid hormone in cardiomyocytes. Pflugers Archiv 470(3), 549–558 (2018). https://doi.org/10.1007/s00424-017-2088-6CrossRefPubMed

33.

M.S. Carneiro‐Ramos, G.P. Diniz, A.P. Nadu, J. Almeida, R.L.P. Vieira, R.A.S. Santos, M.L.M. Barreto‐Chaves, Blockage of angiotensin II type 2 receptor prevents thyroxine‐mediated cardiac hypertrophy by blocking Akt activation. Basic Res. Cardiol. 105(3), 325–335 (2010). https://doi.org/10.1007/s00395-010-0089-0CrossRefPubMed

34.

A. Parthasarathy, V. Gopi, S. Umadevi, A. Simna, M.J.U. Sheik, H. Divya, E. Vellaichamy, Suppression of atrial natriuretic peptide/natriuretic peptide receptor-A- mediated signaling up-regulates angiotensin-II-induced collagen synthesis in adult cardiac fibroblasts. Mol. Cell Biochem. 378(1-2), 217–228 (2013). https://doi.org/10.1007/s11010-013-1612-zCrossRefPubMed

35.

G. Sacripanti, M. Nguyen, L. Lorenzini, S. Frascarelli, A. Saba, R. Zucchi, S. Ghelardoni, 3,5-Diiodo-l-Thyronine Increases Glucose Consumption in Cardiomyoblasts Without Affecting the Contractile Performance in Rat Heart. Front. Endocrinol. 30(9), 282 (2018). https://doi.org/10.3389/fendo.2018.00282CrossRef

36.

A. Rozanski, A.P.C. Takano, P.N. Kato, A.G. Soares, C. Lellis-Santos, J.C. Campos, J.C.B. Ferreira, M.L.M. Barreto-Chaves, A.S. Moriscot, M-protein is down-regulated in cardiac hypertrophy driven by thyroid hormone in rats. Mol. Endocrinol. 27(12), 2055–65 (2013). https://doi.org/10.1210/me.2013-1018CrossRefPubMedPubMedCentral

37.

S.M. Chacko, K.G. Nevin, R. Dhanyakrishnan, B.P. Kumar, Protective effect of p-coumaric acid against doxorubicin induced toxicity in H9c2 cardiomyoblast cell lines. Toxicol. Rep. 2, 1213–1221 (2015). https://doi.org/10.1016/j.toxrep.2015.08.002CrossRefPubMedPubMedCentral

38.

J.H. Lee, D.H. Kim, M.A. Kim, K.H. Jung, K.H. Lee, Mitochondrial ROS-Mediated Metabolic and Cytotoxic Effects of Isoproterenol on Cardiomyocytes Are p53-Dependent and Reversed by Curcumin. Molecules 27(4), 1346 (2022). https://doi.org/10.3390/molecules27041346CrossRefPubMedPubMedCentral

39.

M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 7(72), 248–54 (1976). https://doi.org/10.1006/abio.1976.9999CrossRef

40.

J.W. Knowles, G. Esposito, L. Mao, J.R. Hagaman, J.E. Fox, O. Smithies, H.A. Rockman, N. Maeda, Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient. mice. J. Clin. Invest. 107(8), 975–984 (2001). https://doi.org/10.1172/jci11273CrossRefPubMed

41.

I. Kishimoto, K. Rossi, D.L. Garbers, A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl Acad. Sci. USA 98(5), 2703–2706 (2001). https://doi.org/10.1073/pnas.051625598CrossRefPubMedPubMedCentral

42.

M.L. Barreto-Chaves, N. Senger, M. Fevereiro, A.C. Parletta, A. Takano, Impact of hyperthyroidism on cardiac hypertrophy. Endocr. Connect. 9(3), R59–69 (2020). https://doi.org/10.1530/EC-19-0543CrossRefPubMedPubMedCentral

43.

S. Ventrella, I. Klein, Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist 4(5), 391–399 (1994). https://doi.org/10.1097/00019616-199409000-00010CrossRef

44.

R.D. Utiger, β-Adrenergic-antagonist therapy for hyperthyroid Graves’ disease. N. Engl. J. Med 310(24), 1597–1598 (1984). https://doi.org/10.1056/NEJM198406143102410CrossRefPubMed

45.

I. Klein, K. Ojamaa, Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344(7), 501–509 (2001). https://doi.org/10.1056/NEJM200102153440707CrossRefPubMed

46.

H.A. Rockman, W.J. Koch, R.J. Lefkowitz, Seven-transmembrane-spanning receptors and heart function. Nature 415(68), 206–12 (2002). https://doi.org/10.1038/415206aCrossRefPubMed

47.

A.S.R. Araujo, G.P. Diniz, F.E.R. Seibel, G. Branchini, M.F.M. Ribeiro, I.S. Brum, N. Khaper, M.L.M. Barreto-Chaves, A.B. Bello-Klein, Reactive oxygen and nitrogen species balance in the determination of thyroid hormones-induced cardiac hypertrophy mediated by renin- angiotensin system. Mol. Cell Endocrinol. 333(1), 78–84 (2011). https://doi.org/10.1016/j.mce.2010.12.018CrossRefPubMed

48.

H. Yaomeng, L. Tongxin, G. Shichao, L. Shuyu, Z. Xiaoran, L. Ying, L. Dangyang, L. Weimin, L. Yang, L. Kunshen, Z. Zheng, L. Chao, Investigating the Role of NPR1 in Dilated Cardiomyopathy and its Potential as a Therapeutic Target for Glucocorticoid Therapy. Front. Pharmacol. 14, 1290253 (2023). https://doi.org/10.3389/fphar.2023.1290253CrossRef

49.

C. Nunn, M.X. Zou, A.J. Sobiesiak, A.A. Roy, L. Kirshenbaum, P. Chidiac, RGS2 inhibits β-adrenergic receptor-induced cardiomyocyte hypertrophy. Cell Signal 22(8), 1231–1239 (2010). https://doi.org/10.1016/j.cellsig.2010.03.015CrossRefPubMed

50.

G.X. Zhang, S. Kimura, A. Nishiyama, T. Shokoji, M. Rahman, L. Yao, Y. Abe, Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc. Res. 65(1), 230e238 (2005). https://doi.org/10.1016/j.cardiores.2004.08.013CrossRef

51.

P. Venditti, S. Di. Meo, Thyroid hormone-induced oxidative stress. Cell. Mol. Life Sci 63(4), 414–434 (2006). https://doi.org/10.1007/s00018-005-5457-9

52.

G.P. Diniz, M.S. Carneiro-Ramos, M.L.M. Barreto-Chaves, Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK- 3beta/mTOR signaling pathway. Basic Res. Cardiol. 104(6), 653–67 (2009). https://doi.org/10.1007/s00395-009-0043-1CrossRefPubMed

53.

C.H. Huang, F.T. Wang, Y.D. Hsuuw, F.J. Huang, W.H. Chan, Non-embryotoxic dosage of alternariol aggravates ochratoxin A-triggered deleterious effects on embryonic development through ROS-dependent apoptotic processes. Toxicol. Res. 10(6), 1211–1222 (2021). https://doi.org/10.1093/toxres/tfab112CrossRef

54.

Y. Zhang, S. Su, W. Li, Y. Ma, J. Shen, Y. Wang, Y. Shen, J. Chen, Y. Ji, Y. Xie, H. Ma, M. Xiang, Piezo1-Mediated Mechanotransduction Promotes Cardiac Hypertrophy by Impairing Calcium Homeostasis to Activate Calpain/Calcineurin Signaling. Hypertension 78(3), 647–660 (2021). https://doi.org/10.1161/HYPERTENSIONAHA.121.17177CrossRefPubMed

55.

A. Kaumann, S. Bartel, P. Molenaar, L. Sanders, K. Burrell, D. Vetter, P. Hempel, P. Karczewski, E. Krause, Activation of β2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C protein in ventricular myocardium from patients with terminal heart failure. Circulation 99(1), 65–72 (1999). https://doi.org/10.1161/01.cir.99.1.65CrossRefPubMed

56.

W. Dillmann, Cellular action of thyroid hormone on the heart. Thyroid 12(6), 447–52 (2002). https://doi.org/10.1089/105072502760143809CrossRefPubMed

57.

F. Vargas, J. Moreno, I. Rodriguez-Gomez, R. Wangensteen, A. Osuna, M. Alvarez-Guerra, J. Garcia-Estan, Vascular and renal function in experimental thyroid disorders. Eur. J. Endocrinol. 154(2), 197–212 (2006). https://doi.org/10.1530/eje.1.02093CrossRefPubMed

58.

F. Cioffi, R. Senese, A. Lanni, F. Goglia, Thyroid hormones and mitochondria: with a brief look at derivatives and analogues. Mol. Cell Endocrinol. 379(1), 51–61 (2013). https://doi.org/10.1016/j.mce.2013.06.006CrossRefPubMed

59.

T. Ines, G. Benjamin, J. Angelo, B. Doruntina, R. Rene, O. Barbara, F. Wolfgang, T. Corina, T3-induced enhancement of mitochondrial Ca2+ uptake as a boost for mitochondrial metabolism. Free Radical Biol. Med 181, 197–208 (2022). https://doi.org/10.1016/j.freeradbiomed.2022.01.024CrossRef

60.

T. Ide, H. Tsutsui, S. Hayashidani, D. Kang, N. Suematsu, K. Nakamura, A. Takeshita, Mitochondrial DNA Damage and Dysfunction Associated With Oxidative Stress in Failing Hearts After Myocardial Infarction. Circ. Res. 88(5), 529–535 (2001). https://doi.org/10.1161/01.res.88.5.529CrossRefPubMed

61.

D.M. Deborah, L.R. Lincoln, Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J. Mol. Cell. Cardiol. 51(1), 0–71 (2011). https://doi.org/10.1016/j.yjmcc.2011.03.013CrossRef

62.

E.J. Tsai, D.A. Kass, Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol. Ther. 122(3), 216–38 (2009). https://doi.org/10.1016/j.pharmthera.2009.02.009CrossRefPubMedPubMedCentral

63.

N. Senger, M. Melo, G. Diniz, M. Campagnole-Santos, R. Santos, M. Barreto-Chaves, Angiotensin-(1-7) reduces cardiac effects of thyroid hormone by GSK3Β/NFATc3 signaling pathway. Clin. Sci. 132(11), 1117–1133 (2018). https://doi.org/10.1042/CS20171606CrossRef

Titel: Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling
verfasst von: Gopinath Nagaraj
Elangovan Vellaichamy
Publikationsdatum: 07.05.2024
Verlag: Springer US
Erschienen in: Endocrine
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-024-03849-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen